|
|
Volumn 523, Issue 7562, 2015, Pages 509-510
|
|
Antibody drugs for Alzheimer's show glimmers of promise
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ADUCANUMAB;
AMYLOID BETA PROTEIN;
CRENEZUMAB;
GANTENERUMAB;
PLACEBO;
SOLANEZUMAB;
MONOCLONAL ANTIBODY;
ANTIBODY;
COGNITION;
DISEASE CONTROL;
DRUG;
HEALTH CARE;
HEALTH POLICY;
NERVOUS SYSTEM DISORDER;
PROTEIN;
ALZHEIMER DISEASE;
CLINICAL TRIAL (TOPIC);
COGNITIVE DEFECT;
DISEASE COURSE;
DISEASE SEVERITY;
DRUG MEGADOSE;
GENETIC RISK;
HUMAN;
MENTAL DETERIORATION;
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
PROTEIN TARGETING;
SHORT SURVEY;
TREATMENT OUTCOME;
ANTAGONISTS AND INHIBITORS;
EARLY INTERVENTION;
METABOLISM;
PSYCHOLOGY;
UNITED STATES;
ALZHEIMER DISEASE;
AMYLOID BETA-PEPTIDES;
ANTIBODIES, MONOCLONAL;
ANTIBODIES, MONOCLONAL, HUMANIZED;
CLINICAL TRIALS AS TOPIC;
DISEASE PROGRESSION;
EARLY MEDICAL INTERVENTION;
HUMANS;
|
|
EID: 84938394820
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/nature.2015.18031 Document Type: Short Survey |
|
Times cited : (51)
|
|
References (0)
|
